5-ethenyl-4-propan-2-yl-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-ethenyl-4-propan-2-yl-1H-pyrazole
• 化学式: C₈H₁₂N₂
• 分子量: 136.19
• InChiKey: KNNBTXIRVAZKEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] CDK INHIBITORS<br/>[FR] INHIBITEURS DE CDK
  申请人：QILU REGOR THERAPEUTICS INC

  公开号：WO2020224568A1

  公开（公告）日：2020-11-12

  Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

  提供的是一种由结构式（I）表示的化合物，或者其药用盐，或者其立体异构体，用于治疗癌症。
• Protein Kinase Conjugates and Inhibitors
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20170174691A1

  公开（公告）日：2017-06-22

  The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

  该发明涉及含有蛋白激酶的蛋白共轭物，该蛋白激酶在ATP结合位点含有半胱氨酸残基，并且与该半胱氨酸残基共价且不可逆地结合的抑制剂，从而不可逆地抑制了蛋白激酶的活性。该发明还涉及不可逆地抑制蛋白激酶的化合物。
• RAS INHIBITORS AND USES THEREOF
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160046661A1

  公开（公告）日：2016-02-18

  Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.

  本文描述了式（I）-（II）的化合物，以及其药学上可接受的盐和制药组合物。还提供了涉及创新化合物或组合物的方法和工具包，用于治疗或预防受试者的增殖性疾病，如癌症（例如肺癌，大肠癌，胰腺癌，胆道癌或子宫内膜癌），良性肿瘤，血管生成，炎症性疾病，自身炎症性疾病和自身免疫性疾病。
• Heteroaryl compounds and uses thereof
  申请人：Celgene CAR LLC

  公开号：US10189794B2

  公开（公告）日：2019-01-29

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物及其使用方法。
• Protein kinase conjugates and inhibitors
  申请人：Celgene Avilomics Research, Inc.

  公开号：US10662195B2

  公开（公告）日：2020-05-26

  The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

  本发明涉及一种蛋白质共轭物，其中含有一种在 ATP 结合位点中含有半胱氨酸残基的蛋白激酶和一种与所述半胱氨酸残基共价且不可逆地结合的抑制剂，从而不可逆地抑制蛋白激酶的活性。本发明还涉及不可逆地抑制蛋白激酶的化合物。